NCT01855074View on ClinicalTrials.gov

An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
SchizophreniaSchizophreniform DisorderSchizoaffective Disorder
Interventions
DRUG

Risperidone

Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.

All Listed Sponsors
lead

Janssen-Cilag Ltd.

INDUSTRY

NCT01855074 - An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders | Biotech Hunter | Biotech Hunter